CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of this document have been redacted and have been separately filed with the Commission. JOINT VENTURE AND LICENSE OPTION AGREEMENT BY AND BETWEEN TG THERAPEUTICS, INC. AND NOVIMMUNE S.A....Joint Venture and License Option Agreement • August 9th, 2018 • Tg Therapeutics, Inc. • Pharmaceutical preparations • New York
This JOINT VENTURE AND LICENSE OPTION AGREEMENT (the “Agreement”) is entered into on June 18, 2018 (the “Effective Date”) between Novimmune SA, a Swiss company having an address at 14 ch. des Aulx, 1228 Plan-Les-Ouates, Geneva, Switzerland (“NOVIMMUNE”) and TG Therapeutics, Inc., a Delaware corporation, with a place of business at 2 Gansevoort Street | 9th Floor, New York, NY, USA (“TGTX”). Novimmune and TGTX are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Standard Contracts
JOINT VENTURE AND LICENSE OPTION AGREEMENTJoint Venture and License Option Agreement • November 14th, 2012 • Tg Therapeutics, Inc. • Pharmaceutical preparations • New York
This JOINT VENTURE AND LICENSE OPTION AGREEMENT (the “Agreement”) is entered into on August 15, 2012 (the “Effective Date”) between Rhizen Pharmaceuticals S A, a company incorporated under the laws of Switzerland, with a place of business at Fritz-Courvoisier 40, CH-2300 La Chaux-de-Fonds, Switzerland (“Rhizen”), and TG Therapeutics, Inc., a Delaware corporation, with a place of business at 787 Seventh Avenue, New York, NY (“TGTX”). Rhizen and TGTX are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
